Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients
- 496 Downloads
The possibility of detection of suppressor genes methylation in circulating free DNA (cf-DNA) of cancer patients and the lack of methylation in healthy individuals makes this epigenetic alternation an ideal diagnostic marker of neoplastic processes. Moreover, hypermethylation in several genes promoter was described as a biomarker of lung cancer. Methylation in the gene encoding doublecortin-like kinase 1 (DCLK1) is observed in patients with colorectal cancer and cholangiocarcinoma. However, there are no studies concerning DCLK1 methylation in lung cancer patients. The aims of the study was to evaluate the frequency of DCLK1 promoter methylation in cf-DNA of lung cancer patients and of healthy persons as well as the usefulness of this test for predicting the lung cancer course.
Materials and methods
DCLK1 methylation status was evaluated in DNA isolated from peripheral blood plasma from 65 lung cancer patients and 95 healthy individuals. After DNA bisulfitation, DCLK1 methylation was determined using the qMSP-PCR technique. Moreover, the presence of DCLK1 methylation was correlated with the overall survival (OS) probability of lung cancer patients.
DCLK1 promoter methylation was detected in 32 lung cancer patients (49.2 %) and 8 healthy individuals (8.4 %). The methylation of the region before transcription start site (TSS) and the region after TSS of DCLK1 gene was detected in 28 and 11 patients, respectively. In seven cases (10.8 %), the DCLK1 promoter methylation in both regions was reported simultaneously. The methylation was observed slightly frequently in patients with small cell lung cancer (75 % of SCLC patients). The median overall survival of patients with DCLK1 promoter methylation was lower than that of patients without DCLK1 gene modification (p = <0.001, HR = 4.235).
The evaluation of DCLK1 promoter region methylation may be useful in both early diagnosis and prediction of the course of lung cancer.
KeywordsLung cancer DNA methylation DCLK1 Free-circulating DNA
The study was sponsored by the Polpharma Scientific Foundation.
Compliance with ethical standards
Conflict of interest
Informed consent was obtained from all individual participants included in the study. The research involved human participants.
- 5.Ruth EB, Knight L, Greystoke A, Blackhall FH, Hughes A, Dive C, et al. DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights. 2007;2:307–19.Google Scholar
- 6.Melissa A, Edwards, Pashayar P, Neavin DR, Brown MA. Methylation in tumorigenesis, methylation—from DNA, RNA and histones to diseases and treatment. Prof. Anica Dricu (Ed.), InTech 2012; 119–135. ISBN: 978-953-51-0881-8.Google Scholar
- 7.Jin H, Ma Y, Shen Q, Wang X. Circulating methylated DNA as biomarkers for cancer detection, methylation—from DNA, RNA and histones to diseases and treatment. Prof. Anica Dricu (Ed.), InTech 2012; 137–152, ISBN: 978-953-51-0881-8.Google Scholar
- 13.Deep JS, Sidhu S, Chandel A, Thapliyal S, Garg C. Aberrant methylation in promoters of GSTP1, p16, p14, and RASSF1A Genes in smokers of North India. ISRN Pulmonol. 2012;2012: Art. ID 247631. doi:10.5402/2012/247631
- 14.Vaissière T, Hung RJ, Zaridze D, Moukeria A, Cuenin C, Fasolo V, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA Methylation of specific genes and its association with gender and cancer risk factors. Cancer Res. 2009;69:243–52.CrossRefPubMedPubMedCentralGoogle Scholar